258 related articles for article (PubMed ID: 34365980)
21. Early evaluation of severe immune checkpoint inhibitor-associated myocarditis: a real-world clinical practice.
Tang X; Li Y; Huang H; Shi R; Shen LT; Qian WL; Yang ZG
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8345-8357. PubMed ID: 37076643
[TBL] [Abstract][Full Text] [Related]
22. Immune Checkpoint Inhibitor-Associated Myocarditis.
Ganatra S; Neilan TG
Oncologist; 2018 Aug; 23(8):879-886. PubMed ID: 29802219
[TBL] [Abstract][Full Text] [Related]
23. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition.
Naqash AR; Appah E; Yang LV; Muzaffar M; Marie MA; Mccallen JD; Macherla S; Liles D; Walker PR
J Immunother Cancer; 2019 Jul; 7(1):169. PubMed ID: 31277704
[TBL] [Abstract][Full Text] [Related]
24. Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy.
Palaskas NL; Segura A; Lelenwa L; Siddiqui BA; Subudhi SK; Lopez-Mattei J; Durand JB; Deswal A; Zhao B; Maximilian Buja L; Iliescu C
Eur J Heart Fail; 2021 Oct; 23(10):1725-1735. PubMed ID: 34114291
[TBL] [Abstract][Full Text] [Related]
25. Clinical Characteristics and Outcomes in Immune Checkpoint Inhibitor Therapy-Associated Myocarditis.
Thakker RA; Lee MA; Albaeni A; Elbadawi A; Suthar KH; Perez C; Sonstein LK; Farr NM; Venkatesan R; Khalife W; Berbarie RF; Chatila KF
Cardiol Res; 2021 Oct; 12(5):270-278. PubMed ID: 34691324
[TBL] [Abstract][Full Text] [Related]
26. Immunomodulatory treatment of immune checkpoint inhibitor-induced myocarditis: Pathway toward precision-based therapy.
Balanescu DV; Donisan T; Palaskas N; Lopez-Mattei J; Kim PY; Buja LM; McNamara DM; Kobashigawa JA; Durand JB; Iliescu CA
Cardiovasc Pathol; 2020; 47():107211. PubMed ID: 32268262
[TBL] [Abstract][Full Text] [Related]
27. Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis.
Salem JE; Bretagne M; Abbar B; Leonard-Louis S; Ederhy S; Redheuil A; Boussouar S; Nguyen LS; Procureur A; Stein F; Fenioux C; Devos P; Gougis P; Dres M; Demoule A; Psimaras D; Lenglet T; Maisonobe T; De Chambrun MP; Hekimian G; Straus C; Gonzalez-Bermejo J; Klatzmann D; Rigolet A; Guillaume-Jugnot P; Champtiaux N; Benveniste O; Weiss N; Saheb S; Rouvier P; Plu I; Gandjbakhch E; Kerneis M; Hammoudi N; Zahr N; Llontop C; Morelot-Panzini C; Lehmann L; Qin J; Moslehi JJ; Rosenzwajg M; Similowski T; Allenbach Y
Cancer Discov; 2023 May; 13(5):1100-1115. PubMed ID: 36815259
[TBL] [Abstract][Full Text] [Related]
28. Neural Net Modeling of Checkpoint Inhibitor Related Myocarditis and Steroid Response.
Stefanovic F; Gomez-Caminero A; Jacobs DM; Subramanian P; Puzanov I; Chilbert MR; Feuerstein SG; Yatsynovich Y; Switzer B; Schentag JJ
Clin Pharmacol; 2022; 14():69-90. PubMed ID: 35975122
[TBL] [Abstract][Full Text] [Related]
29. The spectrum of cardiovascular complications related to immune-checkpoint inhibitor treatment : Including myocarditis and the new entity of non inflammatory left ventricular dysfunction.
Andres MS; Ramalingam S; Rosen SD; Baksi J; Khattar R; Kirichenko Y; Young K; Yousaf N; Okines A; Huddart R; Harrington K; Furness AJS; Turajlic S; Pickering L; Popat S; Larkin J; Lyon AR
Cardiooncology; 2022 Nov; 8(1):21. PubMed ID: 36424659
[TBL] [Abstract][Full Text] [Related]
30. Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study.
Xie X; Wang L; Li Y; Xu Y; Wu J; Lin X; Lin W; Mai Q; Chen Z; Zhang J; Xie Z; Qin Y; Liu M; Lu M; Luo B; Zhou C
Front Immunol; 2022; 13():879900. PubMed ID: 35924238
[TBL] [Abstract][Full Text] [Related]
31. Immune Checkpoint Inhibitors-Associated Myocarditis: Diagnosis, Treatment and Current Status on Rechallenge.
Frascaro F; Bianchi N; Sanguettoli F; Marchini F; Meossi S; Zanarelli L; Tonet E; Serenelli M; Guardigli G; Campo G; Calabrò L; Pavasini R
J Clin Med; 2023 Dec; 12(24):. PubMed ID: 38137806
[TBL] [Abstract][Full Text] [Related]
32. Immunopathogenesis of Immune Checkpoint Inhibitor Induced Myocarditis: Insights from Experimental Models and Treatment Implications.
Wong CK; Lam TH; Liao SY; Lau YM; Tse HF; So BYF
Biomedicines; 2023 Jan; 11(1):. PubMed ID: 36672615
[TBL] [Abstract][Full Text] [Related]
33. Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis.
Awadalla M; Mahmood SS; Groarke JD; Hassan MZO; Nohria A; Rokicki A; Murphy SP; Mercaldo ND; Zhang L; Zlotoff DA; Reynolds KL; Alvi RM; Banerji D; Liu S; Heinzerling LM; Jones-O'Connor M; Bakar RB; Cohen JV; Kirchberger MC; Sullivan RJ; Gupta D; Mulligan CP; Shah SP; Ganatra S; Rizvi MA; Sahni G; Tocchetti CG; Lawrence DP; Mahmoudi M; Devereux RB; Forrestal BJ; Mandawat A; Lyon AR; Chen CL; Barac A; Hung J; Thavendiranathan P; Picard MH; Thuny F; Ederhy S; Fradley MG; Neilan TG
J Am Coll Cardiol; 2020 Feb; 75(5):467-478. PubMed ID: 32029128
[TBL] [Abstract][Full Text] [Related]
34. The prognostic value of global myocardium strain by CMR-feature tracking in immune checkpoint inhibitor-associated myocarditis.
Zhao SH; Yun H; Chen CZ; Chen YY; Lin JY; Zeng MS; Liu TS; Pan CZ; Jin H
Eur Radiol; 2022 Nov; 32(11):7657-7667. PubMed ID: 35567603
[TBL] [Abstract][Full Text] [Related]
35. Immune Checkpoint Inhibitor-Induced Myositis: a Case Report and Literature Review.
Kadota H; Gono T; Shirai Y; Okazaki Y; Takeno M; Kuwana M
Curr Rheumatol Rep; 2019 Feb; 21(4):10. PubMed ID: 30790071
[TBL] [Abstract][Full Text] [Related]
36. Case Report: Glucocorticoid Effect Observation in a Ureteral Urothelial Cancer Patient With ICI-Associated Myocarditis and Multiple Organ Injuries.
Hu X; Wei Y; Shuai X
Front Immunol; 2021; 12():799077. PubMed ID: 34975911
[TBL] [Abstract][Full Text] [Related]
37. Successful Therapy for Myocarditis Concomitant With Complete Heart Block After Pembrolizumab Treatment for Head and Neck Squamous Cell Carcinoma: A Case Report With Literature Review.
Su L; Liu C; Wu W; Cui Y; Wu M; Chen H
Front Cardiovasc Med; 2022; 9():898756. PubMed ID: 35647073
[TBL] [Abstract][Full Text] [Related]
38. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
39. Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors.
Awadalla M; Golden DLA; Mahmood SS; Alvi RM; Mercaldo ND; Hassan MZO; Banerji D; Rokicki A; Mulligan C; Murphy SPT; Jones-O'Connor M; Cohen JV; Heinzerling LM; Armanious M; Sullivan RJ; Damrongwatanasuk R; Chen CL; Gupta D; Kirchberger MC; Moslehi JJ; Shah SP; Ganatra S; Thavendiranathan P; Rizvi MA; Sahni G; Lyon AR; Tocchetti CG; Mercurio V; Thuny F; Ederhy S; Mahmoudi M; Lawrence DP; Groarke JD; Nohria A; Fradley MG; Reynolds KL; Neilan TG
J Immunother Cancer; 2019 Feb; 7(1):53. PubMed ID: 30795818
[TBL] [Abstract][Full Text] [Related]
40. Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced Myocarditis.
Zhu H; Galdos FX; Lee D; Waliany S; Huang YV; Ryan J; Dang K; Neal JW; Wakelee HA; Reddy SA; Srinivas S; Lin LL; Witteles RM; Maecker HT; Davis MM; Nguyen PK; Wu SM
Circulation; 2022 Jul; 146(4):316-335. PubMed ID: 35762356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
